How has been the historical performance of Brawn Biotech?

Answer:The historical performance of Brawn Biotech shows a modest financial position as of March 2023, with net sales reported at 0.48 crore and total operating income matching this figure. The company incurred total expenditures of 0.48 crore, resulting in an operating profit of 0.24 crore after accounting for other income. The profit before tax stood at 0.22 crore, leading to a profit after tax of 0.19 crore, which translates to an earnings per share (EPS) of 0.39. The profit after tax margin was notably high at 39.58%.

Breakdown:
Brawn Biotech's financial results for March 2023 indicate that the company generated net sales of 0.48 crore, with total operating income also at 0.48 crore. The total expenditure was equal to the operating income, resulting in an operating profit of 0.24 crore, which reflects a gross profit margin of 50.0%. After accounting for taxes, the profit after tax was 0.19 crore, yielding a profit after tax margin of 39.58%. The company's equity capital was reported at 4.90 crore, with reserves at 4.86 crore. The book value per share decreased to 21.03 from previous years, indicating a downward trend in shareholder value. The balance sheet shows total liabilities of 14.37 crore against total assets of the same amount, reflecting a stable but modest financial structure. Overall, Brawn Biotech's performance reveals a company operating at a low revenue level with a high profit margin, yet facing challenges in asset growth and shareholder value.